Cargando…

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma

Feline mammary carcinoma (FMC) is a common neoplasia in cat, being HER2-positive the most prevalent subtype. In woman’s breast cancer, tyrosine kinase inhibitors (TKi) are used as a therapeutic option, by blocking the phosphorylation of the HER2 tyrosine kinase domain. Moreover, clinical trials demo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gameiro, Andreia, Almeida, Filipe, Nascimento, Catarina, Correia, Jorge, Ferreira, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002158/ https://www.ncbi.nlm.nih.gov/pubmed/33800900 http://dx.doi.org/10.3390/pharmaceutics13030346

Ejemplares similares

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
por: Gameiro, Andreia, et al.
Publicado: (2021)

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
por: Valente, Sofia, et al.
Publicado: (2023)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

Anaplastic Mammary Carcinoma in Cat
por: Soares, Maria, et al.
Publicado: (2021)

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications
por: Nascimento, Catarina, et al.
Publicado: (2022)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
por: Soares, Maria, et al.
Publicado: (2016)

Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells
por: Almeida, Filipe, et al.
Publicado: (2021)

Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

Clinical Relevance of the serum CTLA-4 in Cats with Mammary Carcinoma
por: Urbano, Ana Catarina, et al.
Publicado: (2020)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
por: Marques, Cláudia S., et al.
Publicado: (2018)

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes
por: Marques, Cláudia S., et al.
Publicado: (2017)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models
por: Peng, M, et al.
Publicado: (2013)

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2020)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Analytical tool for optimization of position sensors based on eddy currents effect
por: Faria, Andreia, et al.
Publicado: (2022)

A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions
por: Žagar, Žiga, et al.
Publicado: (2023)

Gene expression association study in feline mammary carcinomas
por: Ferreira, Daniela, et al.
Publicado: (2019)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse
por: Peng, M, et al.
Publicado: (2015)

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis
por: Yu, Yushuai, et al.
Publicado: (2023)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_03jaljigc0cbkc4qp74crfuarq